Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.59 |
| ▸ | PPARA | Q07869 | 5/20 | 0.57 |
| ▸ | PPARG | P37231 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | KLK7 | P49862 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL806019 | 0.94 | RAB9A (0.68) | RAB9ASMN1; SMN2ALDH1A1MAPTEPHX2 | |
| SCHEMBL29079360 | 0.92 | MEN1 (0.63) | RAB9ASMN1; SMN2ALDH1A1MAPTEPHX2 | |
| SCHEMBL6558056 | 0.89 | SMN1; SMN2 (0.58) | RAB9ASMN1; SMN2ALDH1A1MAPTEPHX2 | |
| SCHEMBL29079320 | 0.89 | CFD (0.56) | SMN1; SMN2ALDH1A1MAPTPPARAPPARG | |
| SCHEMBL6555975 | 0.88 | PPARA (0.69) | RAB9ASMN1; SMN2ALDH1A1MAPTPPARA | |
| SCHEMBL6557438 | 0.88 | PPARA (0.69) | RAB9ASMN1; SMN2ALDH1A1MAPTPPARA | |
| SCHEMBL6555962 | 0.88 | GAA (0.64) | RAB9ASMN1; SMN2ALDH1A1MAPTPPARA | |
| SCHEMBL14345202 | 0.88 | USP2 (0.56) | RAB9ASMN1; SMN2ALDH1A1MAPTEPHX2 | |
| SCHEMBL12998281 | 0.87 | HPGD (0.62) | SMN1; SMN2ALDH1A1PPARAPPARGMEN1 | |
| SCHEMBL29079373 | 0.86 | ALDH1A1 (0.55) | RAB9ASMN1; SMN2ALDH1A1MAPTPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5122539-A | Allosteric hemoglobin modifiers useful for decreasing oxygen affinity and preserving oxygen carrying capability of stored blood | CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1992-06-16 | — | — | US | claimed |
| US-20070212302-A1 | Preparation and Use of a Stable Formulation of Allosteric Effector Compounds | ALLOS THERAPEUTICS, INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070212302-A1 | Preparation and Use of a Stable Formulation of Allosteric Effector Compounds | ALLOS THERAPEUTICS, INC. (US) | 2007-09-13 | — | — | US | disclosed |
| EP-1468680-A2 | Using allosteric hemoglobin modifiers to decrease oxygen affinity in blood | Virginia Commonwealth University Intellectual Property Foundation, Inc. (US) | 2004-10-20 | — | — | EP | disclosed |
| EP-0585366-B1 | USING ALLOSTERIC HEMOGLOBIN MODIFIERS TO DECREASE OXYGEN AFFINITY IN BLOOD | UNIV VIRGINIA COMMONWEALTH (US) | 2004-04-28 | — | — | EP | disclosed |
| EP-1236711-B1 | Using allosteric hemoglobin modifiers to decrease oxygen affinity in blood | UNIV VIRGINIA COMMONWEALTH (US) | 2004-03-03 | — | — | EP | disclosed |
| EP-1236711-A2 | Using allosteric hemoglobin modifiers to decrease oxygen affinity in blood | Virginia Commonwealth University Intellectual Property Foundation, Inc. (US) | 2002-09-04 | — | — | EP | disclosed |
| US-5927283-A | TREATING DISEASES INVOLVING OXYGEN DEFICIENCY, IN WOUND HEALING, AND IN RESTORING OXYGEN AFFINITY OF STORED BLOOD. | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1999-07-27 | — | — | US | disclosed |
| US-5872282-A | MAINTAIN OXYGEN AFFINITY IN BLOOD WHEN STORED | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1999-02-16 | — | — | US | disclosed |
| US-5731454-A | Allosteric modifiers of hemoglobin useful for decreasing oxygen affinity and preserving oxygen carrying capability of stored blood | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1998-03-24 | — | — | US | disclosed |
| EP-0585366-A1 | USING ALLOSTERIC HEMOGLOBIN MODIFIERS TO DECREASE OXYGEN AFFINITY IN BLOOD | CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1994-03-09 | — | — | EP | disclosed |
| US-5290803-A | Using allosteric hemoglobin modifiers to decrease oxygen affinity in blood | THE CENTER OF INNOVATIVE TECHNOLOGY (US) | 1994-03-01 | — | — | US | disclosed |
| US-5250701-A | 2-(Phthalomidomethylphenoxyalkanoic acid or ester; wound healing agents; antiischemic agents; blood storage; antidepressants; Alzheimer's disease; schizophrenia | CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1993-10-05 | — | — | US | disclosed |
| US-5248785-A | Using allosteric hemoglobin modifiers to decrease oxygen affinity in blood | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1993-09-28 | — | — | US | disclosed |
| WO-1992020335-A1 | USING ALLOSTERIC HEMOGLOBIN MODIFIERS TO DECREASE OXYGEN AFFINITY IN BLOOD | CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1992-11-26 | — | — | WO | disclosed |
| EP-0471811-A4 | ALLOSTERIC HEMOGLOBIN MODIFIERS | — | 1992-11-25 | — | — | EP | disclosed |
| US-5122539-A | Allosteric hemoglobin modifiers useful for decreasing oxygen affinity and preserving oxygen carrying capability of stored blood | CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1992-06-16 | — | — | US | disclosed |
| EP-0471811-A1 | ALLOSTERIC HEMOGLOBIN MODIFIERS. | INNOVATIVE TECH CENTER (US) | 1992-02-26 | — | — | EP | disclosed |
| US-5049695-A | Substituted diphenyl carbamates | CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1991-09-17 | — | — | US | disclosed |
| WO-1991012235-A1 | ALLOSTERIC HEMOGLOBIN MODIFIERS | CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1991-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070212302-A1 | Preparation and Use of a Stable Formulation of Allosteric Effector Compounds | PRKAA2, PDE7A, CHRM3 | RAB9A 2897/4885SMN1; SMN2 718/4885ALDH1A1 3307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.